Square Pharmaceuticals (SQURPHARMA) Q2 25/26 earnings summary

Executive summary

• Consolidated net revenue for the six months ended 31 December 2025 was Tk. 43.38 billion, up from Tk. 37.72 billion year-over-year, reflecting strong recovery and growth in business momentum.

• Profit after tax for the period reached Tk. 14.68 billion, a significant increase from Tk. 12.70 billion in the prior year period.

• Earnings per share (EPS) rose to Tk. 16.56 from Tk. 14.32 year-over-year, and net operating cash flow per share (NOCF) increased to Tk. 13.16 from Tk. 8.28.

Financial highlights

• Gross profit for the six months was Tk. 21.54 billion, up from Tk. 17.82 billion year-over-year.

• Operating profit reached Tk. 13.36 billion, compared to Tk. 11.00 billion in the previous year.

• Income from investments contributed Tk. 3.62 billion, up from Tk. 3.05 billion year-over-year.

• Net assets value (NAV) per share increased to Tk. 162.41 from Tk. 157.88.

Outlook and guidance

• Management notes a strong upward momentum in revenue performance, with both EPS and NOCF per share showing healthy growth after a prior year slowdown due to socio-political factors.